Authors

• Eiichiro Kanda (ORCID: https://orcid.org/0000-0003-0676-096X)
• Naoki Kashihara (ORCID: https://orcid.org/0000-0002-9487-984X)
• Carol A. Pollock (ORCID: https://orcid.org/0000-0001-7167-6495)
• David C. Wheeler (ORCID: https://orcid.org/0000-0001-8121-5182)
• Juan José García Sánchez (ORCID: https://orcid.org/0000-0001-6546-7769)
• Richard Ofori‐Asenso (ORCID: https://orcid.org/0000-0002-6643-3269)
• Steven Fishbane
• Juan Jesús Carrero (ORCID: https://orcid.org/0000-0003-4763-2024)
• Hungta Chen
• Carolyn S.P. Lam (ORCID: https://orcid.org/0000-0003-1903-0018)
• Surendra Pentakota
• Roberto Pecoits-Filho

Institutions

• AstraZeneca (United Kingdom) (GB)
• The University of Sydney (AU)
• National University of Singapore (SG)
• Pontifícia Universidade Católica do Paraná (BR)
• Kawasaki Medical School (JP)
• Royal North Shore Hospital (AU)
• Karolinska Institutet (SE)
• Arbor Research Collaborative for Health (US)
• National Heart Centre Singapore (SG)
• AstraZeneca (Spain) (ES)
• AstraZeneca (United States) (US)
• University College London (GB)

Publication Details

Journal

Advances in Therapy

Published

2024-11-29

DOI

https://doi.org/10.1007/s12325-024-03028-z

Citations

1

Primary Topic

Chronic Kidney Disease and Diabetes

Type

article

Field-Weighted Citation Impact

0.34

Funders

• AstraZeneca